ctRAGE-DIAPH1 interaction antagonist; reduces inflammatory signaling in diabetic mice
RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (KD for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an
in vitro
wound healing assay (IC50 = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-124984 |
| Réf. fabricant | 18787446 |
| Nom chimique ou matériau | N-[4-[7-Cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]acetamide |
| CAS | 2143072-85-7 |
| Quantité | 5 mg |
| Cible | AGER |
| Formule moléculaire | C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> |
| Pureté | 0.98 |
